Putnam BioRevolution ETF
SYNB
SYNB was delisted on the 13th of November, 2025.
5 hedge funds and large institutions have $7.03M invested in Putnam BioRevolution ETF in 2023 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and closing their positions.
93% more capital invested
Capital invested by funds: $3.64M → $7.03M (+$3.39M)
67% more funds holding
Funds holding: 3 → 5 (+2)
58.49% more ownership
Funds ownership: 75.72% → 134.21% (+58%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GT
Glenview Trust
Louisville,
Kentucky
|
+$1.85M |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$558K |
| 3 |
Jane Street
New York
|
+$406K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$3K |
Top Sellers
SYNB Hedge Fund Activity: Q4 2023 in Review
5 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Putnam BioRevolution ETF (SYNB) for Q4 2023, worth a combined $7.03M — up 93% from $3.64M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new SYNB positions and 0 closed out — a net gain of 2 holders — while 2 added to existing stakes and 0 trimmed.
The largest buyer was Glenview Trust, opening a new position worth an estimated $1.85M.
- 5 institutional investors held Putnam BioRevolution ETF (SYNB) as of Q4 2023, up from 3 in Q3 2023.
- Funds reported $7.03M of Putnam BioRevolution ETF stock for Q4 2023, up 93% quarter-over-quarter.
- 2 funds opened new Putnam BioRevolution ETF positions in Q4 2023 and 0 closed out, a net change of +2 holders.
- The largest Putnam BioRevolution ETF buyer in Q4 2023 was Glenview Trust, an estimated $1.85M added.
Based on aggregated 13F filings for Q4 2023.